Royal Philips has announced that it has received 510(k) clearance from the US Food and Drug Administration (US FDA) to market its Avalon CL Fetal Monitoring solution (Avalon CL). The solution provides consistent monitoring of the mother and child, without the burden of managing cables, allowing mothers more freedom of movement during labor.

The product joins the company's existing portfolio of mobility solutions designed for advanced monitoring and connected care across the health continuum, from healthy living and prevention, to diagnosis, treatment, recovery and home care.

"Conventional fetal monitoring solutions present limitations for physicians and patients alike. This latest cableless technology enhances clinician confidence and allows women more flexibility and freedom of movement during labor, which can be very beneficial to the woman and child," said Mr Mike Mancuso, CEO of Philips Healthcare's Patient Care and Monitoring Solutions.